A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA)

Annals of Clinical Microbiology and Antimicrobials

Volumn 15, Issue 1, 2016, Pages

  Akram, Fatma Elzahraa ^a   El Tayeb, Tarek ^b   Abou Aisha, Khaled ^a   El Azizi, Mohamed ^a  

^a German University in Cairo   (Egypt)

^b Cairo University   (Egypt)

Author keywords

Azithromycin; Checkerboard assay; Clarithromycin; Double and triple combinations; Linezolid; Multidrug resistance; Nonconventional antimicrobials; Vancomycin

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; LINEZOLID; SILVER NANOPARTICLE; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION; METAL NANOPARTICLE; SILVER;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLUE LIGHT; CONCENTRATION RESPONSE; CYTOLYSIS; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; MEMBRANE DAMAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LIGHT; MICROBIAL SENSITIVITY TEST; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; PROCEDURES; RADIATION RESPONSE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; DRUG SYNERGISM; LIGHT; LINEZOLID; METAL NANOPARTICLES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHOTOTHERAPY; SILVER; VANCOMYCIN;

EID: 84982141321     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-016-0164-y     Document Type: Article

References (51)

1. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629-41.
2. Franklin DL. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111(9):1265-73.
3. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA. 2002;99(11):7687-92.
4. Lara HH, Garza-Treviño EN, Ixtepan-Turrent L, Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnology. 2011;9:30.
5. Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, Galdiero M. Silver nanoparticles as potential antibacterial agents. Molecules. 2015;20:8856-74.
6. Nowack B, Krug H, Height M. 120 years of nanosilver history: 609 implications for policy makers. Environ Sci Technol. 2011;45(4):1177-83.
7. Bogumiła R, Andrea H, Andreas L, Kenneth AD, Iseult L. Mechanisms of silver nanoparticle release, transformation and toxicity: a critical review of current knowledge and recommendations for future studies and applications. Materials. 2013;6:2295-350.
8. Ansari M, Khan H, Khan A, Malik A, Sultan A, Shahid M, et al. Evaluation of antibacterial activity of silver nanoparticles against MSSA and MRSA on isolates from skin infections. Biol Med. 2011;3(2):141-6.
9. Paredes D, Ortiz C, Torres R. Synthesis, characterization, and evaluation of antibacterial effect of Ag nanoparticles against Escherichia coli O157:H7 and methicillin-resistant Staphylococcus aureus (MRSA). Int J Nanomedicine. 2014;9:1717-29.
10. Abdel Rahim KA, Mohamed AM. Bactericidal and antibiotic synergistic effect of nanosilver against methicillin-resistant Staphylococcus aureus. Jundishapur J Microbiol. 2015;8(11):e25867.
11. Vrcek IV, Zuntar I, Petlevski R, Pavicic I, Dutour SM, Culin M, et al. Comparison of in vitro toxicity of silver ions and silver nanoparticles on human hepatoma cells. Environ Toxicol. 2016;31(6):679-92.
12. D'Britto V, Kapse H, Babrekar H, Pabhune AA, Bhoraskar SV, Premnath V, et al. Silver nanoparticle studded porous polyethylene scaffolds: bacteria struggle to grow on them while mammalian cells thrive. Nanoscale. 2011;3(7):2957-63.
13. Tianhong D, Asheesh G, Clinton KM, Mark SV, George PT, Michael RH. Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond. Drug Resist Updat. 2012;15(4):223-36.
14. Maclean M, McKenzie K, Anderson JG, Gettinby G, MacGregor SJ. 405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control. J Hosp Infect. 2014;88(1):1-11.
15. Enwemeka CS, Williams D, Enwemeka SK, Hollosi S, Yens D. Blue 470-nm light kills methicillin-resistant Staphylococcus aureus (MRSA) in vitro. Photomed Laser Surg. 2009;27(2):221-6.
16. Halstead FD, Thwaite JE, Burt R, Laws TR, Raguse M, Moeller R, et al. Antibacterial activity of blue light against nosocomial wound pathogens growing planktonically and as mature biofilms. Appl Environ Microbiol. 2016;82(13):4006-40016.
17. Jonas D, Grundmann H, Hartung D, Daschner FD, Towner KJ. Evaluation of the mecA femB duplex polymerase chain reaction for detection of methicillin resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999;18(9):643-7.
18. Kapoor S. Preparation, characterization, and surface modification of silver particles. Langmuir. 1998;14(5):1021-5.
19. Clinical and Laboratory Standards Institute (CLSI): methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-approved standards-seventh edition, in CLSI document M7-A7 2002, vol. 26 No. 2, Pennsylvania. p. 16-18.
20. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115(11):849-59.
21. Dykstra MJ, Reuss E. Biological electron microscopy theory, techniques and troubleshooting. 2nd ed. Berlin: Springer; 2003.
22. Gould SW, Cuschieri P, Rollason J, Hilton AC, Easmon S, Fielder MD. The need for continued monitoring of antibiotic resistance patterns in clinical isolates of Staphylococcus aureus from London and Malta. Ann Clin Microbiol Antimicrob. 2010;9:20.
23. Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31(4):365-73.
24. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with healthcare-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109-15.
25. Choi O, Hu Z. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. Environ Sci Technol. 2008;42:4583-8.
26. von Eiff C, Heilmann C, Herrmann M, Peters G. Basic aspects of the pathogenesis of staphylococcal polymer associated infections. Infection. 1999;27(Suppl 1):S7-10.
27. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-32.
28. Khardori N, Yassien M, Wilson K. Tolerance of Staphylococcus epidermidis grown from indwelling vascular catheters to antimicrobial agents. J Ind Microbiol. 1995;15:148-51.
29. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents. 1999;11:217-21.
30. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-22.
31. Gross M, Cramton SE, Götz F, Peschel A. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun. 2001;69:3423-6.
32. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167-93.
33. The European Committee on Antimicrobial Susceptibility Testing (EUCAST): breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. 2015. http://www.eucast.org. Accessed 3 Nov 2015
34. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA. Participants in the CDC convened experts meeting on management of MRSA in the community. strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the centers for disease control and prevention. 2006.
35. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68(1):4-11.
36. Guffey JS, Wilborn J. Effects of combined 405-nm and 880-nm light on Staphylococcus aureus and Pseudomonas aeruginosa in vitro. Photomed Laser Surg. 2006;24(6):680-3.
37. Enwemeka CS, Williams D, Enwemeka SK, Hollosi S, Yens D. Blue 470-nm light kills methicillin-resistant Staphylococcus aureus (MRSA) in vitro. Photomed Laser Surg. 2008;27(2):221-6.
38. Lazar V. Quorum sensing in biofilms-how to destroy the bacterial citadels or their cohesion power? Anaerobe. 2011;17:280-5.
39. Periasamy S, Joo HS, Duong AC, Bach TH, Tan VY, Chatterjee SS, et al. How Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl Acad Sci USA. 2012;109:1281-6.
40. Morones JR, Elechiguerra JL, Camacho A, Ramirez JT. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16:2346.
41. Danilcauk M, Lund A, Saldo J, Yamada H, Michalik J. Conduction electron spin resonance of small silver particles. Spectrochim Acta Part A Mol Biomol Spectrosc. 2006;63:189-91.
42. Kim JS, Kuk E, Yu K, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007;3:95-101.
43. Maclean M, Macgregor SJ, Anderson JG, Woolsey GA. The role of oxygen in the visible-light inactivation of Staphylococcus aureus. J Photochem Photobiol B. 2008;92(3):180-4.
44. Nour ES, El-Tayeb TA, Abou-Aisha K, El-Azizi M. In vitro and in vivo antimicrobial activity of combined therapy of silver nanoparticles and visible blue light against Pseudomonas aeruginosa. Int J Nanomedicine. 2016;11:1749-58.
45. Wu L, McGrane RS, Beattie GA. Light regulation of swarming motility in Pseudomonas syringae integrates signaling pathways mediated by a bacteriophytochrome and a LOV protein. MBio. 2013;4(3):e00334.
46. Barkovits K, Schubert B, Heine S, Scheer M, Frankenberg-Dinkel N. Function of the bacteriophytochrome BphP in the RpoS/Las quorum sensing network of Pseudomonas aeruginosa. Microbiology. 2011;157(Pt 6):1651-64.
47. Ruden S, Hilpert K, Berditsch M, Wadhwani P, Ulrich AS. Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides. Antimicrob Agents Chemother. 2009;53(8):3538-40.
48. Hwang IS, Hwang JH, Choi H, Kim KJ, Lee DG. Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved. J Med Microbiol. 2012;61:1719-26.
49. Smekalova M, Aragon V, Panacek A, Prucek R, Zboril R, Kvitek L. Enhanced antibacterial effect of antibiotics in combination with silver nanoparticles against animal pathogens. Vet J. 2015;209:174-9.
50. Kalita S, Kandimalla R, Sharma KK, Kataki AC, Deka M, Kotoky J. Amoxicillin functionalized gold nanoparticles reverts MRSA resistance. Mater Sci Eng C Mater Biol Appl. 2016;61:720-7.
51. Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev Anti Infect Ther. 2011;9(11):1035-52.